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Abstract: Hyponatremia is a common phenomenon in psychiatry oc-
curring as an adverse effect to drugs or following polydipsia. We
performed a retrospective in-depth analysis of hyponatremia cases in a
large unselected population of psychiatric inpatients. During a 3-year
period, all cases of hyponatremia were identified among patients ad-
mitted to a large psychiatric state and university hospital by the
institution’s electronic laboratory database. Demographic, treatment-
related, and laboratory data were obtained by consecutive chart review,
respectively. Hyponatremia occurred in 347 (4.9%) of 7113 cases, of
which the majority (78%) displayed only a mild manifestation. Symp-
toms were recorded in 28.8% of cases, already occurred in mild forms,
and comprised gait impairment (45%, including falls), confusion (30%),
sedation (26%), and dyspepsia (41%). Age, female sex, nonpsychiatric
drug polypharmacyVparticularly with thiazides and/or angiotensin-
converting enzyme inhibitorsVand diagnosis of a mood disorder were
associated with more severe hyponatremia, respectively. The proportion
of hyponatremic patients treated with venlafaxine, trazodone, carba-
mazepine, oxcarbazepine, and first-generation antipsychotics, respec-
tively, was significantly higher in the hyponatremia sample than in the
normonatremic population. This was, surprisingly, not the case with
selective serotonin reuptake inhibitors or any other antidepressant drug
class. We found prescription with second-generation antipsychotics to
be significantly associated with less severe hyponatremia.
Hyponatremia may be mainly attributed to the syndrome of inap-
propriate antidiuretic hormone secretion, as indicated by decreased se-
rum osmolarity in our sample. Besides old age and female sex, treatment
with certain drugsVrather than whole drug classesVcarries a substan-
tially increased risk.
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(J Clin Psychopharmacol 2013;33: 799Y805)
Hyponatremia, usually defined as a serum sodium concen-tration ([Na+]) below 135 mEq/L, is the most prevalent
electrolyte aberrance encountered in hospitalized patients in
both general medical and psychiatric institutions.1,2 Signs and
symptoms mainly entail neuropsychiatric and gastrointestinal
manifestations. Hyponatremia has been linked with increased
health care resource use and costs.3 It can cause significant
morbidity and, by way of an osmotic demyelinating encepha-
lopathy, may lead to serious consequences, such as lethargy,
confusion, coma, and occasionally death.4,5 However, clinical
symptoms vary and depend mainly on severity and abruptness of
onset. Overt symptoms generally do not appear until [Na+] falls
below 130 mEq/L.6 Among psychiatric patients, hyponatremia is
believed to be frequently underdiagnosed because clinical signs
may mimic psychopathological symptoms of the underlying
condition.7
Physiological serum [Na+] is maintained within tight limits
through a complex homeostatic system involving hypothalamic
osmoreceptors and peripheral baroreceptors regulating water in-
take and urine output via changes in thirst and the neurohypo-
physeal secretion of the antidiuretic hormone arginine-vasopressin
(AVP).8 Thus, excessive water intake or inappropriate release of
AVP in the absence of osmotic stimuli, respectively are among
the most common pathomechanisms of hyponatremia. The latter
condition is known as the syndrome of inappropriate antidiuretic
hormone secretion (SIADH) and occurs, among an array of other
causes, as an adverse effect of a large number of psychotropic
and other drugs.7,9,10 Above all, a wealth of case reports, case-
control, and population-based studies have implicated antide-
pressants, such as tricyclic antidepressants (TCAs), selective
serotonin reuptake inhibitors (SSRIs), selective serotonin
and norepinephrine reuptake inhibitors (SNRIs), and certain
anticonvulsantsVmainly carbamazepine and oxcarbazepineV in
hyponatremia of this origin.11Y13 The most prevalent nonpsychi-
atric drugs associated with SIADH-induced hyponatremia are
thiazide diuretics and angiotensin-converting enzyme inhibitors
(ACEIs), among others.7
Age and female sex are established major risk factors for
treatment-emergent hyponatremia. Moreover, in psychiatry,
special patient populations are at particular risk to develop this
type of electrolyte disturbance. These include mainly schizo-
phrenia patients with polydipsia or others with compulsive
drinking behavior and individuals with anorexia-related sur-
reptitious water loading.14 Occurrence of polydipsia and poly-
uria in schizophrenia were reported already in the early part of
the 20th century, before specific psychiatric drug treatment
became available.15 The prevalence of hyponatremia has been
estimated as 15% and 11% in general and psychiatric hospital
settings, respectively.16,17 However, numbers vary considerably,
depending on threshold definitions and subpopulations under
analysis. Despite the apparent clinical significance of the issue,
our knowledge on prevalence, risk factors, and drugs involved
in treatment-related hyponatremia is mainly confined to anti-
depressants, in particular SSRIs and venlafaxine.18,19 Moreover,
it still relies to a large extent on anecdotal data from case studies
and the investigation of small patient cohorts in special
subpopulations.2
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The objective of the present study was thus to analyze in an
unselected population of hospitalized psychiatric patients the
frequency and risk factors as well as the clinically most relevant
symptoms of hyponatremia. We carried out an in-depth analysis
of a complete set of hyponatremia cases that occurred during
inpatient treatments of 3 consecutive years in a large psychiatric
state and university hospital.
MATERIALS AND METHODS
Study Design
Data for this retrospective analysis were drawn from re-
cords of all patients of the Department of Psychiatry and Psy-
chotherapy, University Hospital, Düsseldorf, Germany, who
were hospitalized from January 1, 2004, through December 31,
2006. Quality standards in this institution require close moni-
toring of routine laboratory parameters, including serum [Na+],
in all patients receiving psychiatric drug treatment. All cases of
hyponatremia (serum [Na+] G135 mEq/L) that occurred during
this time episode were identified using the hospital’s electronic
laboratory database. The first pathological serum [Na+] mea-
sured during the treatment course in a given case was referred to
as ‘‘index hyponatremia.’’ A thorough chart analysis of all
hyponatremia cases was undertaken. Basic demographic vari-
ables as well as the following relevant illness- and treatment-
related data were obtained:
& complete psychiatric and medical diagnoses;
& complete psychiatric and medical drugs prescribed at time
point of index hyponatremia;
& serum [Na+] (mEq/L) at time point of index hyponatremia
and subsequent values in case of serial measurements;
& other laboratory parameters: serum levels of potassium (mEq/L),
urea (mg/dL), glucose (mg/dL), and estimated glomerular fil-
tration rate (eGFR) at time point of index hyponatremia; and
& serum osmolarity, calculated according toBhagat et al20: 1.86
[Na+] (mEq/L) + 0.056  serum glucose (mg/dL) + 0.17 
serum urea (mg/dL) + 9.
For assessment of symptoms, information was extracted
from the daily follow-up reports of nursing staff and treating
physicians from 2 days before until 5 days after the date of in-
dex hyponatremia. Symptoms were operationalized into the
following entities: (i) dizziness/clouding of consciousness, (ii)
psychomotor retardation, (iii) confusion, (iv) gait disturbance,
(v) fall events, (vi) seizure activity, and (vii) gastrointestinal
symptoms (nausea/vomiting, diarrhea). Symptoms were con-
sidered only if, according to the chart documentation, they had
occurred in close temporal relation to the index hyponatremia
and if they were distinct from those of the psychopathology of
the underlying psychiatric condition of the patient.
To determine the hyponatremia prevalence of single com-
pounds and drug classes, the number of prescriptions of the
respective substance in the hyponatremia sample had to be re-
lated to that in the inpatient population of the defined 3-year
investigation period. Because exact information on prescription
rates of the whole population was impossible to obtain, pre-
scription rates were estimated using the method of the psychiatric
drug surveillance program AMSP (‘‘Arzneimittelsicherheit in der
Psychiatrie’’) in which the hospital participates.21 In this project,
the data on drug use are derived from 2 reference days per year
(ie, 6 reference days within the 3-year period). On these reference
days, all administered drugs and their dosages are recorded for all
patients of the institution. From these data, estimated prescription
rates for the whole population are calculated for compounds and
drug classes of interest.22 We focused our analysis on antide-
pressants, high-potency first-generation antipsychotics (FGAs),
second-generation antipsychotics (SGAs), and mood stabilizers.
Statistical Analysis
The hyponatremia prevalence of a given drug/drug class
was determined as the number of cases found to be treated with
this drug/drug class in the hyponatremia sample N[hypo], di-
vided by the number of patients exposed to this drug/drug class
in the whole population under study (N[total]). For comparison
of hyponatremia prevalences between different drugs/drug
classes, prevalences were compared on a one-by-one basis with
the average hyponatremia prevalence of all other drugs, re-
spectively, using the W2 test or Fisher exact test, as appropriate.
Data are depicted together with their 95% confidence intervals
(95% CIs).
Other data were provided as mean T SD or median/range,
as appropriate, for continuous variables or in terms of number
and percentage for categorical variables, respectively. For anal-
ysis of the relation of [Na+] to various demographic, treatment-
related and laboratory parameters, [Na+] values of the
hyponatremia case sample were collapsed into quintiles, with
cases displaying the lowest [Na+] appearing in the fifth quintile.
Continuous variables of interest were compared across [Na+]
quintiles using analysis of variance or the Kruskal-Wallis rank
sum test, as appropriate. Dunn post hoc test was used in case
of multiple comparisons. Categorical variables were analyzed
with the W2 test with Yates correction. Correlations were cal-
culated using the Spearman rank correlation coefficient. Sig-
nificance was set at P G 0.05.
RESULTS
Demographic and Illness-Related Data
From 2004 through 2006, a total of N[total] = 7113 psy-
chiatric inpatient treatments were registered in our hospital.
Hyponatremia ([Na+]G135 mEq/L) was found in N[hypo] = 347
cases (4.9%). The median age of the case sample was 67 years
(range, 21Y101 years). There was a predominance of elderly
subjects (Q60 years) in N[hypo] (odds ratio, 11.11; 95% CI,
8.82Y14.0; P G 0.0001). Among the subgroup of patients
60 years or older in N[total], the hyponatremia prevalence
was 16%. Whereas the sex proportion of nonhyponatremic
cases was rather balanced, women prevailed in N[hypo] (odds
ratio, 1.78; 95% CI, 1.42Y2.23; P G 0.0001).
Most prevalent psychiatric diagnoses in hyponatremia
cases were mood disorders (60%, n = 209; mainly depression),
followed by substance-related disorders (n = 118, 34%) with a
proportion of 89% with dual diagnoses (n = 105), schizophrenia
and schizoaffective disorders (32%, n = 112), dementias and
other organic psychiatric disorders (n = 107, 31%), and others
(n = 21, 6%). Twenty-three percent of cases (n = 178) had more
than 1 psychiatric diagnoses. More than three-fourths (78%) of
cases had mild ([Na+]: 130-134 mEq/L) and 20% had moderate
([Na+]: 120-129 mEq/L) hyponatremia. Only a small minority
of cases (2%) displayed severe hyponatremia ([Na+] G120 mEq/L).
The mean [Na+] of the N[hypo] was 131.2 T 3.9 mEq/L.
Symptoms were recorded in 100 cases (28.8%) (Table 1).
The mean [Na+] of symptomatic patients was 131.0 T 4.0mmol/L
and almost identical to that of the complete sample. There was
no difference regarding age and sex distribution among symp-
tomatic versus asymptomatic hyponatremia cases. As expected,
symptom occurrence depended on the severity of hyponatremia
(Supplementary Table A, Supplemental Digital Content 1,
http://links.lww.com/JCP/A209). Neuropsychiatric symptoms
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such as gait impairment, confusion, dizziness/clouding of con-
sciousness, and psychomotor slowing were recorded. Gait im-
pairment, including falls, was the most prevalent symptom. The
respective chart documentations included predominantly trouble
maintaining balance or climbing stairs and reduced gait speed
and stride length, among others. Seizures occurred in only
1.2% of cases. Gastrointestinal symptoms (dyspepsia) were also
noted in a considerable proportion of cases.
Serum [Na+] and Characteristic Baseline,
Treatment-Related, and Laboratory Parameters
The median (interquintile range) or mean T SD values of
salient demographic, treatment-related, and chemical laboratory
variables of the case sample by quintiles of [Na+] are provided
in Supplementary Table A (Supplemental Digital Content 1).
Patients in the fifth quintile were significantly older and more
often women. Interestingly, low [Na+] was associated with a
shorter duration of treatment, probably because of early referral
of symptomatic hyponatremic patients to other (medical) de-
partments. Regarding major Axis I psychiatric diagnoses, there
was no association between hyponatremia and a diagnosis of
schizophrenia/schizoaffective disorder or a substance use
disorder, respectively. However, patients with low [Na+] were
significantly more often diagnosed with a mood disorder
(Supplementary Table A, Supplemental Digital Content 1).
The mean serum osmolarity in the samplewas 265.3 mOsm/kg
H2O, which is below the physiological lower limit of 275 mOsm/kg
H2O.9 Serum osmolarity was negatively correlated with the
eGFR (r = j0.42. P G 0.0001). These results may point toward
SIADH as the main overall underlying cause of hyponatremia in
the case sample. In accordance, low serum osmolarity was sig-
nificantly associated with the degree of severity of hyponatremia
as evidenced by Supplementary Table A (Supplemental Digital
Content 1). Of the various chemical parameters under study,
only serum chloride concentration [Clj] correlated with [Na+].
There was no significant association with serum potassium
concentration [K+], eGFR, urea, glucose, or hematocrit across
[Na+] quintiles, respectively (Supplementary Table A, Supple-
mental Digital Content 1).
Hyponatremia Prevalences of Psychiatric
and Medical Drugs and Drug Classes
There was no difference regarding the prescribed number
of total and psychiatric drugs across quintiles. However, the
number of nonpsychiatric drugs (mainly ACEI, thiazide di-
uretics, opiate analgesics, nonsteroidal anti-inflammatory drugs,
proton pump inhibitors) was significantly higher in the fifth
[Na+] quintile (Supplementary Table A, Supplemental Digital
Content 1). Of interest, regarding the proportions of relevant
psychiatric drugs and drug classes found across [Na+] quintiles,
no significant difference was observed apart from a lower pre-
scription rate of SGAs in the lowest [Na+] quintile. By contrast,
a significant impact of nonpsychiatric drugs on hyponatremia
severity was found. Patients at the lower end of [Na+] were
significantly more often treated with ACEIs and combinations
of ACEIs and thiazide diuretics, respectively, and also showed a
strong trend of a higher treatment frequency with thiazides
alone. Taken together, prescriptions with medical drugs, espe-
cially ACEIs and thiazide diuretics, and medical combination
therapy seem to convey a particular risk to develop more severe
degrees of hyponatremia. This was not the case for any psy-
chotropic drug or drug class, including SSRIs. Moreover,
polypharmacy with thiazides and/or ACEI was found signifi-
cantly more often in SSRI-treated cases in the fifth (lowest [Na+])
versus first quintile (P G 0.0023; data not depicted).
To estimate overall hyponatremia prevalences for salient
psychotropic substances, we related the proportion of a given
compound/drug class found in the hyponatremia sample N[hypo]
to that calculated for the nonhyponatremic part of the whole
population N[total], respectively. The results are shown in
Figure 1. Because of small case numbers for the majority of
single drugs, most data were merged to major drug groups and
are presented as a whole.
Antidepressants
Treatment with the TCAs amitriptyline, clomipramine,
doxepine, nortriptyline, trimipramine, and the tetracyclic anti-
depressant maprotiline was documented in the hyponatremia
sample N[hypo]. As depicted in Figure 1A, TCAs showed a
hyponatremia prevalence of overall 4.5%, which was not sig-
nificantly different from the average of all other drugs. Of note,
regarding the SSRIs (3.5%), which have been implicated in
hyponatremia in many case reports and some retrospective and
cohort studies, the hyponatremia prevalence did not exceed the
average prevalence of all other psychotropic drugs. In contrast,
venlafaxine treatment was significantly more prevalent among
the hyponatremic sample (Fig. 1A). Of the remaining antide-
pressants not associated with one of the mentioned classes,
mirtazapine had an average and trazodone had a surprisingly
high hyponatremia rate. However, the 95% CI for the latter was
wide, and the number of treated patients was relatively small, so
this finding should be interpreted with caution.
TABLE 1. Symptoms of Hyponatremia Cases
Symptom n %* of Patients With Symptoms (n = 100) % of Patients With Hyponatremia (n = 347)
Neuropsychiatric
Dizziness/clouding of consciousness 26 26 7.5
Psychomotor retardation 14 14 4.0
Confusion 30 30 8.6
Gait impairment 45 45 12.9
Falls 15 15 4.4
Seizures 4 4 1.2
Gastrointestinal
Nausea/vomiting/diarrhea 41 41 11.8
*Sum exceeding 100% due to multiple symptoms.
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Antipsychotics
‘‘Conventional’’ high-potency FGAs were associated with
a significantly higher hyponatremia rate in the case sample
compared with an average rate for SGAs (Fig. 1B). Moreover,
SGA prescription was associated with less severe hyponatremia.
Mood Stabilizers
According to expectations, oxcarbazepine and carbamaz-
epine had the highest hyponatremia rates in this group and one
of the highest overall. Hyponatremia was significantly less




We have investigated a complete data set derived from a
large and unselected psychiatric inpatient population, which we
consider a strength of this report. Furthermore, salient epide-
miological and treatment-related data and particularly elaborate
chart documentation on symptoms were made available to draw
meaningful conclusions regarding various clinically relevant
aspects of the topic. However, as the study is retrospective, it
has inherent shortcomings. Most relevant, the frequent use
of multiple medications and the presence of concomitant med-
ical illnesses make causal relationships difficult to estab-
lish. Hyponatremia in psychiatry is a complex and multifaceted
phenomenon that may occur as an adverse drug reaction as well
as in close relation to certain diagnoses, above all as a result of
polydipsia in schizophrenia, a frequently neglected and cer-
tainly underdiagnosed phenomenon.2 High normalized diurnal
weight gain, concomitant low urinary osmolality, and of course
increased daily fluid intake are indicative of polydipsia. Be-
cause these features were not regularly available in the charts,
we focused our analysis on other treatment-related parameters,
mainly drug exposure, being aware that lack of consideration of
polydipsia as a potential confounding factor is a limitation to
our study. We thus tried to take care not to draw direct causal
linkages to drug treatment but rather provide a descriptive
approach.
Because of the large population size, we were not able to
list the drugs prescribed to individual patients in the complete
population N[total]. Thus, we had to estimate prescription rates
of the drugs in question (as detailed in Materials and Methods),
which may be viewed as another limitation. This method,
however, as established within the framework of the AMSP
program, has been used successfully in previous retrospective
drug safety studies.21,23
Regarding symptom analysis, we had to rely on staff
documentation at the time point of the first pathological [Na+]
defined as index hyponatremia. This may have led to underes-
timation of symptom severity, which may have increased par-
allel to progression of hyponatremia in the further course.
General and Epidemiological Considerations
In this study, we provide a retrospective analysis of a large
unselected population of psychiatric inpatients, spanning a 3-year
period in a primary and secondary psychiatric care environ-
ment and using 135 mEq/L as the low normal limit of [Na+].
The hyponatremia prevalence was 4.9% in the overall popula-
tion and 16% in the elderly subpopulation, with mild mani-
festations in the majority of cases. In the literature, estimates of
hyponatremia prevalence depend on clinical circumstances (eg,
medical, surgical, psychiatric, elderly patients, etc) and on
predefined cutoff levels. Thus, data in general hospital settings
widely range from 2.5% to 30%.24 A recent systematic review
revealed a prevalence of 6.0% in normal and 22.2% in geriatric
wards, respectively.25 In psychiatry, data exist mainly on spe-
cialized psychiatric populations, such as schizophrenia patients
with polydipsia (25%),17 older patients treated with SSRIs or
venlafaxine (39%),18 and inpatients of psychogeriatric wards
(7.7%).
In contrast to the whole inpatient population, the majority
of cases in the hyponatremia sample was 60 years or older, and
age correlated with hyponatremia severity. This is consistent
with the current literature where age is an established risk factor
for hyponatremia,1,2,9,23 probably due to multiple reasons. For
example, older patients are more likely to have multiple medical
FIGURE 1. Prevalences of hyponatremia associated with various
psychotropic drugs/drug classes in psychiatric inpatients. A,
Antidepressants and (B) antipsychotics and mood stabilizers. The
hyponatremia prevalence of a given drug/drug class was
determined as its number in the hyponatremia sample (N[hypo])
related to the number of patients exposed to the respective
drug/drug class in the whole study population (N[total]). Values
are shown together with their 95% CIs. The hyponatremia
prevalence of a given drug/drug class was compared with that
of all others, respectively (W2 or Fisher exact test, as appropriate).
Thus, the comparator’s mean of a respective drug may differ
from the group mean of all drugs (indicated by the dotted line
for orientation), which explains why, in case of venlafaxine,
the group mean lies within the depicted 95% CI. *P G 0.05,
**P G 0.01. CBZ indicates carbamazepine; Li, lithium; MIR,
mirtazapine; OXC, oxcarbazepine; TRA, trazodone; VEN,
venlafaxine; VPA, valproate.
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diagnoses and thus are prescribed more drugs, including such
with known potential to induce hyponatremia such as ACEI,
thiazides, and so on. Moreover, age-related alterations of renal
function impede water homeostasis and sodium metabolism
causing reduced drug clearance.26 The vast majority of hypo-
natremia cases in the elderly27 and most of the cases occur-
ring in psychiatric patients2 have been attributed to SIADH. In
the present study, we found an association of hyponatremia
severity and low serum osmolarity indicative of the presence of
SIADH.
We found the likelihood of hyponatremia approximately
doubled for female patients. It is known that hyponatremia in
general and drug-induced hyponatremia in particular dispro-
portionally affect women.7 The exact underlying cause of this
finding is still unknown. However, a variety of sex differences
of the physiological sodium and water metabolism exists, which
may depend at least in part on ovarian hormone activity. It is
known, for example, that the antidiuretic responsiveness to AVP
and its analog on desmopressin is higher in women than in
men.28 In addition, sex-related variances in the function of
several sodium transport systems across membranes have been
found, resulting in differences in intracellular and extracellular
[Na+], favoring a relative state of lower extracellular [Na+] and a
higher sensitivity to drug-induced hyponatremia in women.29
Symptoms
Confusion, sedation, gait impairment, and (rarely) seizures
were neuropsychiatric symptoms recorded in our sample, indi-
cating the presence of osmotic encephalopathy at least in a
considerable proportion of cases.9 In addition, gastrointestinal
symptoms were common. Gait impairment (including falls) was
the most prevalent condition in our sample. This finding seems
to be of particular clinical importance because subtle gait im-
pairment may easily be overlooked, and special precautions may
prevent significant consecutive morbidity and socioeconomic
consequences.30,31 In fact, it has been shown earlier that even
chronic hyponatremia conveys a considerable risk of falls due to
gait and attention impairment.32 As expected, symptom occur-
rence recorded in the charts clearly correlated with hyponatremia
severity. Nevertheless, we found a considerable proportion of
symptomatic cases already in mild forms confirming previous
observations.33,34 We are aware that cases with [Na+] of greater
than 130 mEq/L may in part represent a variation of normality.
However, we have included them in our analysis because of
overwhelming evidence of an increased independent risk of
adverse outcome and even mortality with mild and very mild
hyponatremia.35Y37
Association of Hyponatremia With Psychotropic
Compounds and Drug Classes
One of the aims of our study was to relate the presence of
hyponatremia in a complete case sample during a defined pe-
riod to the treatment with psychotropic drugs of interest. As
already pointed out, our retrospective data were not suitable to
causally link hyponatremia with certain drug treatments in our
case sample because of frequent polypharmacy and the impos-
sibility to exclude underlying etiological factors that are diag-
nosis related. Our approach was thus mainly descriptive;
however, it may at least allow for indirect conclusions. Indeed,
despite this limitation and as outlined below, salient results are
well suited to findings in the current literature regarding the risk
of hyponatremia pertaining to particular drugs or drug groups.
Drug-induced hyponatremia may occur (1) secondary to
SIADH by inducing excess hypothalamic production and hy-
pophyseal release of AVP without the appropriate physiological
stimuli (ie, antidepressants, antipsychotic drugs),2 (2) through
potentiation of the endogenous AVP effect at the renal tubule
level (ie, several anticonvulsants/mood stabilizers), (3) in re-
sponse to reduction of the threshold for AVP secretion by re-
setting the osmostat, and (4) increased urinary loss of sodium
(ie, diuretics, mainly thiazides).7 The hyponatremia risk seems
to be higher when multiple mechanisms are involved. Carba-
mazepine and oxcarbazepine, for example, can elicit hypona-
tremia via mechanisms (1), (2), and (3).38Y42 Accordingly, in
the present study, the hyponatremia prevalence of these com-
pounds was 3- and 6-fold increased compared with the aver-
age, respectively. Values were almost identical to those found
in a previous study in epilepsy patients (13.5% and 29.9% in
our work, respectively).43 Thus, hyponatremia seems to be a
common adverse effect of these anticonvulsants, independent
of diagnosis. In contrast, valproate and lithium displayed
much lower hyponatremia rates in our sample. Hence, if a
mood stabilizer is indicated in patients particularly at risk
for hyponatremia, valproate and lithium should be favored in
this respect.
Neurohypophyseal release of AVP can be directly stimu-
lated by serotonin (5-HT) and other monoamines.44 This
mechanism may at least partly underlie the adverse SIADH-
mediated hyponatremia secondary to antidepressants because
most of them, including TCAs, SNRIs, and SSRIs, are potent
combined monoamine or selective 5-HT reuptake inhibitors.
The TCAs have been among the first psychotropic drug classes
in which hyponatremia has been observed.45 In our study,
hyponatremia prevalence of TCAs was close to the average of
all other psychotropic drugs. Of interest, hyponatremia preva-
lence of SSRI was also not significantly higher than the aver-
age. This drug class has been implicated in hyponatremia and
falls in many case reports46 and a previous case-control study.12
Nevertheless, our findings are in line with a previous retro-
spective study that also failed to detect an increased hypona-
tremia risk associated with SSRI use.31 Accordingly, Letmaier
et al23 also found just an average risk for SSRI treatment alone,
which significantly increased in case of combination therapy
with ACEI, diuretics, and both. Likewise, in our sample, all
patients of the fifth quintile (most severe hyponatremia) who
received an SSRI were significantly more often comedicated
with a thiazide or an ACEI or both than the SSRI cases of
the least severe hyponatremic first quintile. Hence, hypona-
tremia secondary to SSRI treatment may become relevant pri-
marily in the presence of other risk-conveying drugs or
conditions. For the SNRI venlafaxine, we found an increased
hyponatremia prevalence in accord with prior evidence.2,12,23 A
surprising finding was the strong association of hyponatremia
with trazodone treatment. However, the large CI has to be con-
sidered. So far, no observations of hyponatremia secondary to
trazodone other than in toxic dose ranges47Y49 have been
published.
In a recent review of case reports and case series regarding
hyponatremia due to antipsychotic drug treatment, Meulendijks
et al50 report on an association of both FGAs and SGAs with
hyponatremia. However, systematic studies on this topic are
lacking, and polydipsia as a frequent symptom in schizophrenia
is a major confounding factor. Our data provide evidence that
FGAs are associated with an increased risk of hyponatremia as
compared with SGAs. As a matter of fact, it has been suggested
that FGA-mediated long-term dopamine D2 receptor blockade
may overly sensitize D2 receptors, a mechanism known to ele-
vate AVP levels,50 which could explain this observation.
Second-generation antipsychotics such as clozapine, on the
other hand, have low D2 receptorYbinding affinities. Thus, D2
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receptor supersensitivity may be normalized or avoided upon
SGA treatment, resulting in less hyponatremia induction. In
fact, clozapine is thought to exert even salutary effects on
polydipsia-induced hyponatremia in psychotic patients.51Y53
This would match our observation that, whereas the proportion
of treatments with FGAs was equally distributed among the
quintiles of increasing hyponatremia severity, SGA treatment
was significantly less prevalent in the most severe cases (fifth
quintile). However, others did not find such associations be-
tween antipsychotic use and hyponatremia.54 Thus, more re-
search is warranted regarding this clinically highly relevant
topic, and importantly, future studies need to be controlled for
polydipsia.
Impact of Other Diagnostic and
Treatment-Related Parameters
We did not find any routine laboratory parameter (except
[Clj] as the corresponding anion) to be associated with
hyponatremia severity in our sample. By contrast, the calculated
serum osmolarity showed a high correlation, and the average
values of all severity quintiles in the sample were well below the
lower physiological limit of 275 mOsm/kg H2O as evidenced by
Supplementary Table A (Supplemental Digital Content 1). Al-
though this is not surprising (because the calculation is mainly
based on [Na+]), our data nonetheless provide other indirect
evidence of SIADH as an important pathophysiologic factor at
least in the fifth quintile comprising the most severe hypona-
tremia cases: First, the average serum urea and the hematocrit
were at the lower end of the reference range. Second, we found a
negative correlation between serum osmolarity and eGFR over
the complete hyponatremia sample.
We also analyzed treatment-related parameters such as
somatic comorbidity and polypharmacy. We were able to show
that a higher degree of hyponatremia severity was associated
with prescription of higher numbers of nonpsychiatric rather
than psychiatric drugs. This association was significant for
treatment with ACEIs alone or in combination with thiazides,
which is in line with recent data.23 We did not find a correlation
of hyponatremia severity with the number of prescribed psy-
chiatric drugs or the total number of applied drugs, respectively.
However, there was a significant negative correlation of
hyponatremia severity and days in hospital treatment, which is
probably due to early referral to medical units of symptomatic
cases.
In conclusion, age, female sex, and treatment with partic-
ular psychiatric drugs (venlafaxine, trazodone, carbamazepine,
oxcarbazepine) rather than drug classes as a whole conveyed an
elevated hyponatremia risk in our large psychiatric inpatient
population. Major determinants for hyponatremia severity were
again age and female sex and also polypharmacy with nonpsy-
chiatric drugs, especially ACEI and combined ACEI and thiazide
treatment. Besides gastrointestinal symptoms, neuropsychiatric
signs such as sedation, confusion, and gait impairment are
rather frequent and may occur already in mild cases. Clinicians
are advised to measure serum [Na+] on a regular basis and
should be aware of this underrecognized condition in psychiatric
inpatients that calls for immediate treatment.
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